Medulloblastoma is a malignant pediatric brain cancer that arises from developing cerebellum. Our preliminary data show that medulloblastoma cell survival critically depends on persistent activity of neurodevelopmental pathways that favor proliferation and block differentiation. Small molecule inhibition of the sonic hedgehog or notch pathway kill medulloblastoma cells more effectively than standard chemotherapy agents. Our broad hypothesis is that both hedgehog and notch signaling are necessary for medulloblastoma, but neither is sufficient. Our long term goal is develop and utilize genetically precise mouse models of medulloblastoma to provide insight into disease pathogenesis and understand which molecular pathways are appropriate for therapeutic targeting. We have developed the ND2:SmoA1 mouse model that faithfully recapitulates human medulloblastoma with a 48% tumor incidence and a mean age of diagnosis of 25.7 weeks. In this model, Nmyc and notch signaling are increased in cerebellar tumors but not in non-neoplastic areas of cerebellum.
The specific aims of this project are to 1a) complete a full neuropathologic analysis of ND2:SmoA1 medulloblastomas, 1b) determine by magnetic resonance imaging the limit of detection and rate of growth of ND2:SmoA1 mouse medulloblastoma, 2a) determine whether Nmyc is necessary for the sonic hedgehog component of mouse medulloblastoma development, 2b) determine whether Nmyc is sufficient to induce medulloblastomas in the absence of other shh target induction, 3a) determine whether Hes5 activation by notch2 is necessary for ND2:SmoA1 medulloblastoma and 3b) determine whether transgenic expression of constitutively active notch in GNPs is sufficient to generate medulloblastomas or whether it increases tumor incidence in ND2:SmoA1 or ND2:Nmyc mice when bred onto these backgrounds. The significance of this proposed work is that it will identify the essential elements of sonic hedgehog and notch pathway signaling required for medulloblastoma genesis and provide genetically precise models for testing and prioritizing candidate pathway inhibitors prior to human trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA112350-04
Application #
7414835
Study Section
Special Emphasis Panel (ZRG1-CNBT (01))
Program Officer
Mietz, Judy
Project Start
2005-07-01
Project End
2010-04-30
Budget Start
2008-05-01
Budget End
2010-04-30
Support Year
4
Fiscal Year
2008
Total Cost
$310,300
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Dey, Joyoti; Dubuc, Adrian M; Pedro, Kyle D et al. (2013) MyoD is a tumor suppressor gene in medulloblastoma. Cancer Res 73:6828-37
Dey, Joyoti; Ditzler, Sally; Knoblaugh, Sue E et al. (2012) A distinct Smoothened mutation causes severe cerebellar developmental defects and medulloblastoma in a novel transgenic mouse model. Mol Cell Biol 32:4104-15
Leary, Sarah E S; Olson, James M (2012) The molecular classification of medulloblastoma: driving the next generation clinical trials. Curr Opin Pediatr 24:33-9
Lee, Michelle J; Hatton, Beryl A; Villavicencio, Elisabeth H et al. (2012) Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse medulloblastoma model. Proc Natl Acad Sci U S A 109:7859-64
Stroud, Mark R; Hansen, Stacey J; Olson, James M (2011) In vivo bio-imaging using chlorotoxin-based conjugates. Curr Pharm Des 17:4362-71
Wu, Changfeng; Hansen, Stacey J; Hou, Qiong et al. (2011) Design of highly emissive polymer dot bioconjugates for in vivo tumor targeting. Angew Chem Int Ed Engl 50:3430-4
Akcan, Muharrem; Stroud, Mark R; Hansen, Stacey J et al. (2011) Chemical re-engineering of chlorotoxin improves bioconjugation properties for tumor imaging and targeted therapy. J Med Chem 54:782-7
Lee, Michelle Jeung-Eun; Veiseh, Omid; Bhattarai, Narayan et al. (2010) Rapid pharmacokinetic and biodistribution studies using cholorotoxin-conjugated iron oxide nanoparticles: a novel non-radioactive method. PLoS One 5:e9536
Hatton, B A; Villavicencio, E H; Pritchard, J et al. (2010) Notch signaling is not essential in sonic hedgehog-activated medulloblastoma. Oncogene 29:3865-72
Ravanpay, Ali C; Hansen, Stacey J; Olson, James M (2010) Transcriptional inhibition of REST by NeuroD2 during neuronal differentiation. Mol Cell Neurosci 44:178-89

Showing the most recent 10 out of 19 publications